Single dose of Covid vaccine sufficient for already infected people: Study

The study was designed to assess the immunological memory response in all those patients.

vaccine
Covid-19 vaccine | File photo
Press Trust of India Hyderabad
2 min read Last Updated : Jun 14 2021 | 7:48 PM IST

A single dose of COVID-19 vaccine is sufficient for an infected person as there was a greater antibody response when compared with those who have had no prior infection, according to a study released by AIG Hospitals on Monday.

The city-based AIG Hospitals recently published a study conducted on 260 healthcare workers, who got vaccinated between January 16 and February 5, in the International Journal of Infectious Diseases (a peer-reviewed journal).

The study was designed to assess the immunological memory response in all those patients.

All patients were given the Covishield vaccine.

The study also said Memory T-cell responses elicited by a single dose of vaccine were significantly higher in the previously infected group compared with those who had no prior infection.

Commenting on the impact that this study can have on the overall vaccine administration strategy, Dr. D Nageshwar Reddy, Chairman, AIG Hospitals, and one of the co-authors of the study, said the results show that people who got infected with COVID-19 need not take two doses of vaccine as a single dose can develop robust antibody and memory cell response at par with two-doses for those who didnt get the infection.

This will significantly help at a time when theres a shortage of vaccine in the country and more people can be covered using the saved doses, Dr Reddy said.

Once the requisite number of people are vaccinated for achieving herd immunity, these patients who got infected and received only one dose can take the second dose of the vaccine, he further said.

At this point, all our strategies should be directed at the widespread distribution of available vaccines and to include the maximum number of people at least with a single dose, Dr Reddy added.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusCoronavirus TestsCoronavirus Vaccine

First Published: Jun 14 2021 | 7:45 PM IST

Next Story